Renal cell carcinoma (RCC): Pazopanib is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (RCC).
Soft tissue sarcoma (STS): Pazopanib is indicated for the treatment of patients with advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.
The Phase III trial population excluded patients with gastrointestinal stromal tumour (GIST) or adipocytic STS.